1. Scrip
  2. >>Business
  3. >>Deals

Vertex Spots Potential Bargain Of $60m Entry Into Complement Regulation

Cash-Strapped Catalyst Bio Forced Into Quick Sale

 
• By Andrew McConaghie

Vertex has acquired the full assets to a promising protease-based drug platform from Catalyst, broadening its R&D base once again.

Vertex Mobile
Rights to the assets were handed back by Biogen in March, and have now been acquired in full by Vertex. • Source: Shutterstock

Vertex has acquired the rights of two preclinical candidates from struggling Catalyst Biosciences, giving it entry into the promising field of complement regulation for the low price of $60m.

The two protease-based candidates, CB 2782-PEG and CB 4332, were previously part of a licensing deal between Catalyst and Biogen,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Novo Adds Another Prong To Its RNA Ambitions With Replicate Deal

 
• By Jessica Merrill

Replicate is a clinical-stage company developing a next-generation self-replicating RNA technology. CEO Nathanial Wang talked to Scrip about the deal.

Lilly Obesity Deal Gives Superluminal More Shots On GPCR Goals

 
• By Andrew McConaghie

Superluminal’s CEO Cony D’Cruz believes its focus on GPCRs has already yielded a best-in-class obesity candidate for its own pipeline, as well as its $1bn- plus deal with Eli Lilly.

Norway’s Nykode Upbeat About Cancer Vaccines After Tough Year

 
• By Kevin Grogan

The firm is concentrating on its Keytruda combo for head and neck cancer after being abandoned by Roche and boardroom battles.